Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases

Clin Case Rep. 2021 Sep 7;9(9):e04574. doi: 10.1002/ccr3.4574. eCollection 2021 Sep.

Abstract

Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes.

Keywords: C‐peptide; diabetes mellitus; immune checkpoint inhibitor; insulin secretion.

Publication types

  • Case Reports